logo
Twitter
Discord
Email
logo
SIGA Technologies, Inc.

SIGA Technologies, Inc.

NASDAQ•SIGA
CEO: Dr. Dennis E. Hruby Ph.D.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 1997-09-10
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Contact Information
31 East 62nd Street, New York, NY, 10065, United States
212-672-9100
www.siga.com
Market Cap
$449.00M
P/E (TTM)
5.5
38.1
Dividend Yield
9.6%
52W High
$9.62
52W Low
$4.95
52W Range
28%
Rank34Top 20.2%
5.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$2.62M-73.83%
4-Quarter Trend

EPS

-$0.09-578.72%
4-Quarter Trend

FCF

-$10.10M+36.43%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Revenue Surge Total revenues reached $90.78M USD for nine months, up $33.53M USD from $57.25M USD reported in prior year.
Net Income Improvement Nine-month net income $28.71M USD, significantly exceeding $13.45M USD reported in the comparable nine-month period.
Strong Operating Cash Flow Operating cash flow provided $60.33M USD for nine months, reversing prior year's $7.55M USD cash usage.
Liquidity Position Strengthened Cash and equivalents total $171.96M USD as of September 30, 2025, compared to $155.40M USD at year-end 2024.

Risk Factors

EMA Mpox Review Status EMA reassessment procedure ongoing regarding Tecovirimat-SIGA effectiveness for mpox treatment indications, potentially impacting authorization.
Quarterly Revenue Decline Quarterly revenue fell sharply to $2.62M USD in Q3 2025 from $10.01M USD in Q3 2024, resulting in a net loss.
Government Shutdown Uncertainty Prolonged U.S. Government shutdown risks delaying funding decisions, new contract awards, and suspending ongoing contract work.
Tariff Cost Increase Risk Tariff activity involving U.S. and Europe may materially increase IV TPOXX® overall manufacturing costs, impacting margins.

Outlook

Smallpox PEP Submission Target Targeting Supplemental NDA submission for oral TPOXX® smallpox post-exposure prophylaxis indication in 2026 based on trial results.
Unexercised BARDA Options Unexercised BARDA options total $5.6M USD, but these supportive activities are currently not expected to be required by BARDA.
Future Purchase Commitments Outstanding purchase orders associated with manufacturing obligations total approximately $12.5M USD as of September 30, 2025.
New Accounting Standard Review Evaluating impact of recently issued FASB ASU 2024-03 regarding expense disaggregation disclosures effective in future periods.

Peer Comparison

Revenue (TTM)

Orthofix Medical Inc.OFIX
$818.06M
+4.3%
Emergent BioSolutions Inc.EBS
$783.50M
-30.4%
SNDL Inc.SNDL
$680.39M
+4.4%

Gross Margin (Latest Quarter)

REGENXBIO Inc.RGNX
80.7%
+31.9pp
Orthofix Medical Inc.OFIX
72.2%
+3.5pp
SIGA Technologies, Inc.SIGA
68.5%
+24.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ESPR$798.02M-8.223.0%41.7%
KALV$766.79M-4.0-195.6%2.9%
CTMX$743.54M25.944.5%3.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-68.2%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Mar 9, 2026
|
EPS:-
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $2.62M-73.8%
    |
    EPS: $-0.09-578.7%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $81.12M+271.9%
    |
    EPS: $0.50+1838.0%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $7.04M-72.3%
    |
    EPS: $-0.01-107.1%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 11, 2025|
    Revenue: $138.72M-0.9%
    |
    EPS: $0.83-12.6%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $10.01M+8.4%
    |
    EPS: $0.02-441.8%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $21.81M+271.0%
    |
    EPS: $0.03-163.9%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $25.43M+205.5%
    |
    EPS: $0.14-1202.4%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 12, 2024|
    Revenue: $139.92M+26.3%
    |
    EPS: $0.95+106.5%
    Miss